Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b two-part, multi-center, randomized, double-blind, placebo-controlled study of RPT904 for the treatment of patients with food allergy

Next Previous
Trial Profile

A Phase 2b two-part, multi-center, randomized, double-blind, placebo-controlled study of RPT904 for the treatment of patients with food allergy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozureprubart (Primary)
  • Indications Food hypersensitivity
  • Focus Therapeutic Use
  • Acronyms prestIgE
  • Sponsors RAPT Therapeutics

Most Recent Events

  • 20 Jan 2026 According to a GSK media release, data from the phase 2b trial assessing use of ozureprubart as monotherapy is expected in 2027.
  • 07 Nov 2025 New trial record
  • 27 Oct 2025 According to RAPT therapeutics media release, company initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of ozureprubart (formerly RPT904) in IgE-mediated food allergy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top